I-Mab (IMAB) Stock Price, News, Quote & History

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(Wt)}else s.style.display="block"},f=function(){d.refreshPanel().then(m).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var h=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(to=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===h&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Jt)),notifLabel:document.querySelector(".".concat(Vt))};io(e,n)}))}()}};

NasdaqGM - Delayed Quote • USD

Compare

1.1500 +0.0400 (+3.60%)

At close: September 27 at 4:00 PM EDT

1.1570 +0.01 (+0.61%)

After hours: September 27 at 4:53 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for IMAB

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous Close 1.1100
Open 1.1500
Bid 0.8136 x 200
Ask 1.3900 x 200
Day's Range 1.0800 - 1.1596
52 Week Range 0.9900 - 2.5360
Volume 416,135
Avg. Volume 239,631
Market Cap (intraday) 89.213M
Beta (5Y Monthly) 1.07
PE Ratio (TTM) --
EPS (TTM) -2.2600
Earnings Date Aug 28, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 6.75

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

ir.i-mabbiopharma.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about I-Mab

Recent News: IMAB

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

IMABI-Mab

1.1500

+3.60%

Mkt Cap 89.213M

Industry Biotechnology

ZLABZai Lab Limited

23.63

+4.56%

Mkt Cap 2.354B

Industry Biotechnology

SYRSSyros Pharmaceuticals, Inc.

2.0000

+2.04%

Mkt Cap 53.62M

Industry Biotechnology

BGNEBeiGene, Ltd.

218.42

+2.77%

Mkt Cap 24.376B

Industry Biotechnology

CCCCC4 Therapeutics, Inc.

5.89

-5.46%

Mkt Cap 408.4M

Industry Biotechnology

IOBTIO Biotech, Inc.

1.0600

-0.93%

Mkt Cap 69.834M

Industry Biotechnology

Statistics: IMAB

Valuation Measures

Annual

As of 9/27/2024

Market Cap

89.21M
Enterprise Value

-114.31M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

26.31
Price/Book (mrq)

0.38
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-29.25%
Return on Equity (ttm)

-71.72%
Revenue (ttm)

3.49M
Net Income Avi to Common (ttm)

-205.6M
Diluted EPS (ttm)

-2.2600

Balance Sheet and Cash Flow

Total Cash (mrq)

207.49M
Total Debt/Equity (mrq)

1.67%
Levered Free Cash Flow (ttm)

--

Research Analysis: IMAB

Company Insights: IMAB

Research Reports: IMAB

People Also Watch

ZLAB Zai Lab Limited

23.63

+4.56%

LEGN Legend Biotech Corporation

49.27

+5.17%

ALXO ALX Oncology Holdings Inc.

1.9700

+5.35%

BNR Burning Rock Biotech Limited

3.2500

-1.81%

IGMS IGM Biosciences, Inc.

17.00

+7.19%

ZNTL Zentalis Pharmaceuticals, Inc.

3.7500

+1.63%

KROS Keros Therapeutics, Inc.

56.45

-0.76%

KYMR Kymera Therapeutics, Inc.

48.69

-1.58%

GBIO Generation Bio Co.

2.4300

+4.74%

BGNE BeiGene, Ltd.

218.42

+2.77%

RLAY Relay Therapeutics, Inc.

7.46

+0.81%

ITOS iTeos Therapeutics, Inc.

10.50

+3.30%

BDTX Black Diamond Therapeutics, Inc.

4.2300

-4.08%

RVMD Revolution Medicines, Inc.

44.17

+0.71%

INBX Inhibrx Biosciences, Inc.

15.52

+1.24%

BCYC Bicycle Therapeutics plc

23.21

-0.47%

I-Mab (IMAB) Stock Price, News, Quote & History - Yahoo Finance (2024)

Full Time Employees

Fiscal Year Ends

Sector

Industry

Profitability and Income Statement

Balance Sheet and Cash Flow